IMPORTANT ANTARES PHARMA, INC. INVESTOR REMINDER – LEAD PLAINTIFF DEADLINE RAPIDLY APPROACHING: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed on behalf of investors who purchased Antares

NEW YORK, Dec. 13, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP  announces that a class action lawsuit  has been filed against Antares Pharma, Inc. (“Antares” or the “Company”) (Nasdaq:ATRS) in the United States  District Court for  the District  of New  Jersey on  behalf of  a class  consisting  of investors who purchased or otherwise  acquired Antares securities on from December 21, 2016 through October 12, 2017, inclusive (the  “Class Period”).

Investors who have incurred losses in Antares Pharma, Inc.  securities  are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.

If   you   have incurred losses in the shares  of  Antares  Pharma, Inc. and would like to assist with the litigation process as a lead plaintiff, you may,  no  later than December 22 , 2017, request that the Court appoint you lead plaintiff of the proposed class. Please contact Wolf Haldenstein to learn more about your rights as a shareholder of Antares Pharma, Inc.  

The filed Complaint alleges  that Defendants  made materially  false and  misleading statements  regarding  the  Company’s  business,  operational  and  compliance policies.  Specifically, the Complaint  alleges  that Defendants  made  false and/or misleading statements and/or failed  to disclose that:

• Antares  had  provided insufficient data to the United States Food and Drug Administration (FDA) in connection with its New Drug Application (NDA)  for Xyosted; and
   
• accordingly, Antares had overstated  the approval prospects for  Xyosted; and
   
• as a  result  of the  foregoing,  Antares’ public  statements  were materially false and misleading at all relevant times.  

On October 12, 2017, after the close of trading, Antares disclosed that on October 11,  2017, the Company  received  a letter  from FDA stating  that the  agency  had “identified deficiencies that preclude the  continuation of the discussion  of labeling and post  marketing requirements/commitments” for  Xyosted. 

On this news, the Company’s share  price  fell $1.41, or 37.80%,  to close at $2.32  on October 13, 2017.

Subsequently, on October  20, 2017,  post-market, Antares  announced receipt  of a  Complete Response  Letter  (“CRL”)  from  the  FDA  regarding  the  NDA  for   Xyosted, “indicat[ing] that the FDA cannot approve  the NDA in its present form.”   The Company stated in part that “the  FDA  is concerned that XYOSTED could cause  a clinically meaningful increase in blood  pressure” and also “raised a  concern regarding the occurrence of depression and suicidality.”

Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country.  The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego.  The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.

If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at  www.whafh.com.

## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##

Contact:

Wolf Haldenstein Adler Freeman & Herz LLP
Kevin Cooper, Esq.
Gregory Stone, Director of Case and Financial Analysis
Email: [email protected], [email protected] or [email protected]
Tel: (800) 575-0735 or (212) 545-4774

Attorney Advertising. Prior results do not guarantee or predict a similar outcome.